Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis AG Common Stock (NY: NVS )

99.13 -0.60 (-0.60%)
Streaming Delayed Price Updated: 9:51 AM EST, Jan 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 180,775
Open 99.24
Bid (Size) 99.12 (6)
Ask (Size) 99.15 (1)
Prev. Close 99.73
Today's Range 98.62 - 99.24
52wk Range 92.35 - 120.92
Shares Outstanding N/A
Dividend Yield 3.81%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end. 
Via Benzinga
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients. 
Via Benzinga
Exposures Product Safety

Performance

YTD
+2.05%
+2.05%
1 Month
+0.69%
+0.69%
3 Month
-13.29%
-13.29%
6 Month
-7.96%
-7.96%
1 Year
-8.61%
-8.61%

More News

Read More
Don't overlook NYSE:NVS—it's a hidden gem with strong fundamentals and an attractive price tag.
Via Chartmill
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
Via Benzinga
Exposures Product Safety
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Balancing Dividends and Fundamentals: The Case of NYSE:NVS.
Via Chartmill
Why the dividend investor may take a look at NYSE:NVS.
Via Chartmill
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Via The Motley Fool
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
Via Benzinga
For those who appreciate value investing, NYSE:NVS is a compelling option with its solid fundamentals.
Via Chartmill
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
Via FinancialNewsMedia
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers
From FN Media Group LLC
Via GlobeNewswire
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
Via Benzinga
2 Dividend Stocks to Buy and Hold Forever
Via The Motley Fool
Exploring NYSE:NVS's dividend characteristics.
Via Chartmill
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
Via Investor's Business Daily
Exposures Product Safety
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
Via Benzinga
Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst
Via Benzinga
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington's Program
Via Benzinga
PTC Therapeutics Scores A $2.9 Billion Novartis Deal And Hits Profit-Taking Zone
Via Investor's Business Daily
Is NYSE:NVS suited for dividend investing?
Via Chartmill
Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline
Via Benzinga
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
Via Benzinga
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
Via Investor's Business Daily
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.